FDA Alternatives Webinar Series
As part of FDA’s commitment to promote novel technologies for potential regulatory use, FDA gives developers and others the opportunity to present their new methods and methodologies directly to FDA scientists. Educational opportunities to hear more about new predictive in vitro, in vivo, and in silico methods is vital to ensuring that FDA regulators and researchers have a broad skill set and remain current with cutting-edge science and technology. Developers presented 29 webinars during 2022 and 2023; presentations described in silico models and in vitro platforms such as MPS, organoids, and engineered tissues relevant to contexts including drug-induced liver injury, neurotoxicity, inhalation toxicity, and veterinary medicine. Information for prospective presenters is available on the FDA website.